Skip Navigation

JNCI Journal of the National Cancer Institute 1996 88(20):1467-1471; doi:10.1093/jnci/88.20.1467
© 1996 by Oxford University Press
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Han, C.
Right arrow Articles by Schiller, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Han, C.
Right arrow Articles by Schiller, J. T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 88, No. 20, 1467-1471, October 16, 1996
© 1996 Oxford University Press

Serologic Association Between Human Papillomavirus Type 16 Infection and Esophageal Cancer in Shaanxi Province, China

Chenglong Han, Guibin Qiao, Nancy L. Hubbert, Liangshou Li, Changsheng Sun, Yan Wang, Mingxiao Yan, Dezhong Xu, Yuangui Li, Douglas R. Lowy, John T. Schiller

Laboratory of Cellular Oncology, Division of Basic Sciences, National Cancer Institute Bethesda, MD
Department of Epidemiology, The Fourth Military Medical University Xi'an, People's Republic of China

Correspondence to: John T. Schiller, Ph.D., National Institutes of Health, Bldg. 36, Rm. ID-28, Bethesda, MD 20892-4040

BACKGROUND:: The existence of large geographic variations in the prevalence of esophageal cancer in some countries, such as China, indicates that environmental risk factors may be important in the development of this disease. Some studies have implicated genital-mucosal strains of human papillomaviruses (HPVs) in the etiology of this cancer.

PURPOSE:: We conducted a case-control study in Shaanxi Province, China, an area with a population at high risk for esophageal cancer, to assess the association of this disease with infection by HPV type 16 (HPV16), the most common cancer-associated genital-mucosal HPV type.

METHODS:: Ninety individuals with esophageal cancer and 121 cancer-free control subjects were identified among the patients in two hospitals in Xi'an, Shaanxi Province. The control subjects were matched to the case patients on the basis of age and sex. Blood specimens were drawn from all study subjects, and serum was isolated by routine methods. The presence of HPV16 antibodies in serum samples was determined by use of an enzyme-linked immunosorbent assay (ELISA) that used baculovirus-derived HPV16 virus-like particles as the antigen. A similar ELISA that used bovine papillomavirus type 1 (BPV1) virus-like particles as the antigen controlled for the specificity of HPV16 seroreactivity. Data from the HPV16 and the BPV1 assays were normalized with respect to results obtained in each assay with a control serum of known HPV16 seroreactivity. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to examine the association between HPV16 seroreactivity and esophageal cancer. Reported P values are two-sided.

RESULTS:: The mean seroreactivity to HPV16 virus-like particles was significantly higher for the cancer patients than for the control subjects (mean value±standard deviation = 0.85± 0.22 versus 0.74±0.18; P<.0001). When the cancer patients and control subjects were compared by sex and age groups, the differences in mean seroreactivity remained statistically significant. The difference in mean seroreactivity to BPV1 virus-like particles between cancer patients and control subjects was not statistically significant (0.81± 0.28 versus 0.88 ± 0.32; P = .12); this result was not altered when sex and age groups were compared. By use of a cutoff point for HPV16 seropositivity that was established in studies of cervical neoplasia, 24% of the cancer patients were seropositive compared with 7% of the control subjects, yielding a sexand age-adjusted OR of 4.5 (95% CI = 1.8–11.9). In general, the OR for esophageal cancer increased with increasing HPV16 seroreactivity.

CONCLUSIONS AND IMPLICATIONS:: HPV16 infection may be a risk factor for esophageal cancer. Further studies of the association between HPV16 infection and the incidence of esophageal cancer are needed.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
K. R. Dahlstrom, K. Adler-Storthz, C. J. Etzel, Z. Liu, L. Dillon, A. K. El-Naggar, M. R. Spitz, J. T. Schiller, Q. Wei, and E. M. Sturgis
Human Papillomavirus Type 16 Infection and Squamous Cell Carcinoma of the Head and Neck in Never-Smokers: A Matched Pair Analysis
Clin. Cancer Res., July 1, 2003; 9(7): 2620 - 2626.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
K J Syrjanen
HPV infections and oesophageal cancer
J. Clin. Pathol., October 1, 2002; 55(10): 721 - 728.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. Krüger Kjaer, B. Chackerian, A. J. C. van den Brule, E. I. Svare, G. Paull, J. M. M. Walbomers, J. T. Schiller, J. E. Bock, M. E. Sherman, D. R. Lowy, et al.
High-Risk Human Papillomavirus Is Sexually Transmitted: Evidence from a Follow-Up Study of Virgins Starting Sexual Activity (Intercourse)
Cancer Epidemiol. Biomarkers Prev., February 1, 2001; 10(2): 101 - 106.
[Abstract] [Full Text]


Home page
JNCI J Natl Cancer InstHome page
J. Lagergren, Z. Wang, R. Bergstrom, J. Dillner, and O. Nyren
Human Papillomavirus Infection and Esophageal Cancer: a Nationwide Seroepidemiologic Case-Control Study in Sweden
J Natl Cancer Inst, January 20, 1999; 91(2): 156 - 162.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.